ArticleEuropean journal of drug metabolism and pharmacokinetics2022

Correction to: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment.

Swan Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.